NZ600125A - Methods of treating or preventing acute erythema - Google Patents
Methods of treating or preventing acute erythemaInfo
- Publication number
- NZ600125A NZ600125A NZ60012510A NZ60012510A NZ600125A NZ 600125 A NZ600125 A NZ 600125A NZ 60012510 A NZ60012510 A NZ 60012510A NZ 60012510 A NZ60012510 A NZ 60012510A NZ 600125 A NZ600125 A NZ 600125A
- Authority
- NZ
- New Zealand
- Prior art keywords
- alpha adrenergic
- treating
- acute erythema
- receptor agonist
- adrenergic receptor
- Prior art date
Links
- 206010015150 Erythema Diseases 0.000 title abstract 3
- 230000001154 acute effect Effects 0.000 title abstract 3
- 231100000321 erythema Toxicity 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000000695 adrenergic alpha-agonist Substances 0.000 abstract 4
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 abstract 3
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 abstract 2
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 abstract 2
- 229960003679 brimonidine Drugs 0.000 abstract 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000011200 topical administration Methods 0.000 abstract 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 abstract 1
- 229930182837 (R)-adrenaline Natural products 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 abstract 1
- 229960005139 epinephrine Drugs 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 229960005016 naphazoline Drugs 0.000 abstract 1
- 229960002748 norepinephrine Drugs 0.000 abstract 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 1
- 229960001528 oxymetazoline Drugs 0.000 abstract 1
- 229960001802 phenylephrine Drugs 0.000 abstract 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 abstract 1
- -1 tetrahydrozaline Chemical compound 0.000 abstract 1
- 229960000833 xylometazoline Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25480509P | 2009-10-26 | 2009-10-26 | |
| PCT/US2010/053198 WO2011053487A1 (en) | 2009-10-26 | 2010-10-19 | Methods of treating or preventing acute erythema |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ600125A true NZ600125A (en) | 2014-05-30 |
Family
ID=43922456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ60012510A NZ600125A (en) | 2009-10-26 | 2010-10-19 | Methods of treating or preventing acute erythema |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110224216A1 (https=) |
| EP (1) | EP2493309A4 (https=) |
| JP (1) | JP2013508454A (https=) |
| KR (1) | KR20120125230A (https=) |
| CN (1) | CN102711471A (https=) |
| AU (1) | AU2010313643B2 (https=) |
| BR (1) | BR112012009891A2 (https=) |
| CA (1) | CA2779063A1 (https=) |
| MX (1) | MX2012004890A (https=) |
| NZ (1) | NZ600125A (https=) |
| RU (1) | RU2012122983A (https=) |
| WO (1) | WO2011053487A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
| US7812049B2 (en) | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| US9114188B2 (en) | 2010-01-13 | 2015-08-25 | Allergan, Industrie, S.A.S. | Stable hydrogel compositions including additives |
| US20110172180A1 (en) | 2010-01-13 | 2011-07-14 | Allergan Industrie. Sas | Heat stable hyaluronic acid compositions for dermatological use |
| US8916562B2 (en) | 2010-03-26 | 2014-12-23 | Galderma Research & Development Snc | Methods and compositions for safe and effective treatment of telangiectasia |
| CN106038476B (zh) | 2010-03-26 | 2020-04-17 | 盖尔德马研究及发展公司 | 安全和有效治疗红斑的改进的方法和组合物 |
| US8911713B2 (en) | 2010-06-30 | 2014-12-16 | Galderma Research & Development | Method for preventing or treating skin tumor |
| CA2810746A1 (en) | 2010-06-30 | 2012-01-05 | Galderma Research & Development | Method for preventing or treating skin tumor |
| EP2629757A2 (en) | 2010-10-21 | 2013-08-28 | Galderma S.A. | Brimonidine gel compositions and methods of use |
| US8053427B1 (en) * | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
| JP6225030B2 (ja) | 2011-02-15 | 2017-11-01 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 酒さの症状を治療するためのオキシメタゾリンの薬学的クリーム組成物 |
| UA109359C2 (xx) * | 2011-11-10 | 2015-08-10 | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
| US9283217B2 (en) * | 2011-11-10 | 2016-03-15 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
| CA2911472A1 (en) * | 2013-05-06 | 2014-11-13 | Allergan, Inc. | Alpha adrenergic agonists for the treatment of tissue trauma |
| US20150374686A1 (en) * | 2014-06-30 | 2015-12-31 | Galderma S.A. | Methods of Treating Flushing Associated with Carcinoid Tumors and Carcinoid Syndrome |
| CN106361733A (zh) * | 2015-07-22 | 2017-02-01 | 刘里远 | 外用经穴激动剂 |
| WO2017161432A1 (pt) * | 2016-03-22 | 2017-09-28 | Doris Maria Hexsel | Uso de uma composição farmacêutica destinada ao tratamento do eritema cutâneo das poiquilodermias |
| FR3119986B1 (fr) * | 2021-02-19 | 2024-02-16 | Tarian Pharma | Composition émulsion eau dans huile et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6911196B2 (en) * | 2002-07-31 | 2005-06-28 | Samir I. Hamtini | Topical medicament for treating nappy rash |
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US8410102B2 (en) * | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
| US20050020600A1 (en) * | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
| US7812049B2 (en) * | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| US20050226899A1 (en) * | 2004-04-08 | 2005-10-13 | Mauro Castiglioni | Cosmetic mask composition |
| PT1761266E (pt) * | 2004-05-25 | 2013-06-04 | Galderma Pharma Sa | Compostos, formulações, e métodos para tratamento ou prevenção de distúrbios inflamatórios da pele |
| US7709014B2 (en) * | 2005-10-17 | 2010-05-04 | Yu Ruey J | Hydroxy-oligocarboxylic esters: effects on nerve and use for cutaneous and mucocutaneous organs or sites |
| US20090061020A1 (en) * | 2007-08-31 | 2009-03-05 | Theobald Klaus P | Brimonidine Compositions for Treating Erythema |
| CN106038476B (zh) * | 2010-03-26 | 2020-04-17 | 盖尔德马研究及发展公司 | 安全和有效治疗红斑的改进的方法和组合物 |
| US20120101104A1 (en) * | 2010-10-21 | 2012-04-26 | Galderma S.A. | Topical gel compositions and methods of use |
| US8053427B1 (en) * | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
-
2010
- 2010-10-19 BR BR112012009891A patent/BR112012009891A2/pt active Search and Examination
- 2010-10-19 JP JP2012536876A patent/JP2013508454A/ja active Pending
- 2010-10-19 CA CA2779063A patent/CA2779063A1/en not_active Abandoned
- 2010-10-19 RU RU2012122983/15A patent/RU2012122983A/ru unknown
- 2010-10-19 KR KR1020127013737A patent/KR20120125230A/ko not_active Ceased
- 2010-10-19 EP EP20100827329 patent/EP2493309A4/en not_active Withdrawn
- 2010-10-19 NZ NZ60012510A patent/NZ600125A/en not_active IP Right Cessation
- 2010-10-19 WO PCT/US2010/053198 patent/WO2011053487A1/en not_active Ceased
- 2010-10-19 MX MX2012004890A patent/MX2012004890A/es unknown
- 2010-10-19 CN CN2010800485638A patent/CN102711471A/zh active Pending
- 2010-10-19 AU AU2010313643A patent/AU2010313643B2/en not_active Ceased
- 2010-10-19 US US12/907,543 patent/US20110224216A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012009891A2 (pt) | 2015-09-29 |
| KR20120125230A (ko) | 2012-11-14 |
| CN102711471A (zh) | 2012-10-03 |
| AU2010313643B2 (en) | 2015-11-12 |
| EP2493309A4 (en) | 2013-05-01 |
| CA2779063A1 (en) | 2011-05-05 |
| AU2010313643A1 (en) | 2012-06-07 |
| US20110224216A1 (en) | 2011-09-15 |
| RU2012122983A (ru) | 2014-01-27 |
| WO2011053487A1 (en) | 2011-05-05 |
| MX2012004890A (es) | 2012-09-28 |
| JP2013508454A (ja) | 2013-03-07 |
| EP2493309A1 (en) | 2012-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ600125A (en) | Methods of treating or preventing acute erythema | |
| MX2012004134A (es) | Terapia de combinacion usando un agonista del receptor adrenergico beta 3 y un agente antimuscarinico. | |
| WO2009129433A3 (en) | Alpha adrenergic receptor agonists for treatment of degenerative disc disease | |
| WO2009129432A3 (en) | Alpha adrenergic receptor agonists for treatment of pain and/or inflammation | |
| BR112012012131A2 (pt) | uso de agonistas de receptores adrenérgicos alfa-2 para tratar ou prevenir psoríase | |
| WO2009129494A3 (en) | Alpha and beta adrenergic receptor agonists for treatment of pain and/or inflammation | |
| BR112012025017A2 (pt) | métodos para melhorar a qualidade do sono. | |
| CL2008003595A1 (es) | Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central. | |
| CL2010000188A1 (es) | Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso. | |
| MX2010010300A (es) | Formas de sal de inhibidores del objetivo de rapamicina en mamiferos. | |
| ECSP13012364A (es) | Dispersiones sólidas que contienen inhibidores de quinasas | |
| WO2012047645A3 (en) | Combination treatment for rosacea | |
| RU2013125042A (ru) | Способ предотвращения или лечения опухоли кожи | |
| WO2006018024A3 (en) | Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists | |
| WO2018060463A3 (en) | Treatment of prostate cancer | |
| EA201690895A1 (ru) | Офтальмологический раствор тартрата бримонидина для местного применения | |
| BRPI0808327A2 (pt) | "aparelho de spinner para facilitar a conexão e desconexão de tubulares encadeados e método para facilitar a conexão e desconexão dos tubulares encadeados" | |
| BRPI0517438A (pt) | composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica | |
| WO2009052073A3 (en) | Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists | |
| UA113749C2 (xx) | Композиція для назального застосування з покращеною стабільністю | |
| WO2009129491A3 (en) | Beta adrenergic receptor agonists for treatment of pain and/or inflammation | |
| TN2011000457A1 (en) | Method or system using biomarkers for the monitoring of a treatment | |
| RU2013123043A (ru) | Гелевая композиция для местного применения | |
| CU24303B1 (es) | Compuesto de benzotiazolona | |
| RU2014119879A (ru) | Способ снижения прилива крови к лицу при систематическом использовании ингибиторов фосфодиэстеразы типа 5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 19 OCT 2017 BY CPA GLOBAL Effective date: 20140908 |
|
| LAPS | Patent lapsed |